Zealand Pharma A/S - Asset Resilience Ratio
Zealand Pharma A/S (ZEAL) has an Asset Resilience Ratio of 63.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZEAL total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Zealand Pharma A/S's Asset Resilience Ratio has changed over time. See shareholders equity of Zealand Pharma A/S for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zealand Pharma A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZEAL market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr10.53 Billion | 63.98% |
| Total Liquid Assets | Dkr10.53 Billion | 63.98% |
Asset Resilience Insights
- Very High Liquidity: Zealand Pharma A/S maintains exceptional liquid asset reserves at 63.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zealand Pharma A/S Industry Peers by Asset Resilience Ratio
Compare Zealand Pharma A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Zealand Pharma A/S (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Zealand Pharma A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.98% | Dkr10.53 Billion ≈ $1.65 Billion |
Dkr16.46 Billion ≈ $2.58 Billion |
-17.51pp |
| 2024-12-31 | 81.49% | Dkr7.75 Billion ≈ $1.21 Billion |
Dkr9.51 Billion ≈ $1.49 Billion |
+21.70pp |
| 2023-12-31 | 59.79% | Dkr1.18 Billion ≈ $185.21 Million |
Dkr1.98 Billion ≈ $309.78 Million |
+52.73pp |
| 2022-12-31 | 7.05% | Dkr108.61 Million ≈ $16.99 Million |
Dkr1.54 Billion ≈ $240.91 Million |
-7.41pp |
| 2021-12-31 | 14.46% | Dkr299.04 Million ≈ $46.79 Million |
Dkr2.07 Billion ≈ $323.50 Million |
-0.99pp |
| 2020-12-31 | 15.45% | Dkr297.35 Million ≈ $46.52 Million |
Dkr1.92 Billion ≈ $301.12 Million |
-3.27pp |
| 2019-12-31 | 18.72% | Dkr299.45 Million ≈ $46.85 Million |
Dkr1.60 Billion ≈ $250.26 Million |
-5.56pp |
| 2018-12-31 | 24.28% | Dkr298.61 Million ≈ $46.72 Million |
Dkr1.23 Billion ≈ $192.41 Million |
+14.09pp |
| 2017-12-31 | 10.19% | Dkr75.11 Million ≈ $11.75 Million |
Dkr737.24 Million ≈ $115.35 Million |
+3.16pp |
| 2013-12-31 | 7.03% | Dkr24.38 Million ≈ $3.81 Million |
Dkr346.91 Million ≈ $54.28 Million |
-17.27pp |
| 2012-12-31 | 24.30% | Dkr126.94 Million ≈ $19.86 Million |
Dkr522.40 Million ≈ $81.73 Million |
-7.51pp |
| 2011-12-31 | 31.81% | Dkr149.36 Million ≈ $23.37 Million |
Dkr469.48 Million ≈ $73.45 Million |
+20.05pp |
| 2010-12-31 | 11.76% | Dkr53.00 Million ≈ $8.29 Million |
Dkr450.55 Million ≈ $70.49 Million |
+11.11pp |
| 2009-12-31 | 0.65% | Dkr1.03 Million ≈ $161.78K |
Dkr158.68 Million ≈ $24.83 Million |
-0.41pp |
| 2008-12-31 | 1.06% | Dkr2.40 Million ≈ $375.03K |
Dkr225.24 Million ≈ $35.24 Million |
-0.63pp |
| 2007-12-31 | 1.69% | Dkr4.46 Million ≈ $698.43K |
Dkr263.37 Million ≈ $41.21 Million |
-- |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more